What are evidence‑based over‑the‑counter and prescription options for relieving cough from the common cold?

Checked on February 5, 2026
Disclaimer: Factually can make mistakes. Please verify important information or breaking news. Learn more.

Executive summary

A limited set of remedies has reliable evidence for easing cough from the common cold: honey for symptomatic relief (in adults and children older than 12 months), oral expectorants like guaifenesin with small benefit in adults, and intranasal ipratropium for cough-related rhinorrhea; most other widely used OTC and prescription agents do not shorten the illness or substantially reduce cough severity [1] [2] [3] [4]. Clinical guidelines and reviews emphasize symptomatic care—humidification, saline, rest—and warn that antibiotics or many popular OTC actives (oral phenylephrine, first‑line antihistamine monotherapy, and NSAIDs) are not proven to relieve cough and can carry harm, especially in young children [5] [6] [7] [8].

1. Why cough is hard to treat and what “evidence‑based” means in colds

Cough in the common cold is a symptom of irritated upper airway mucosa caused by dozens of viruses, and trials have struggled with small samples and variable endpoints, so the evidence base is generally low quality; reviewers conclude no therapy reliably shortens both severity and duration of the cold as a whole, so recommendations focus on symptom relief rather than cure [5] [9] [7].

2. Over‑the‑counter options with the best supporting data

The clearest OTC winner for cough relief is honey (for adults and children ≥1 year), which randomized trials and guideline panels found reduces nocturnal cough frequency and improves sleep, though effects are modest and pediatric trials have methodological limits [9] [1] [2]. Guaifenesin, an expectorant, has small evidence of benefit for adults with cough but the improvement is limited and additional research is needed to quantify clinical impact [4]. Simple measures—warm fluids, saline nasal spray or irrigation, humidified air and throat lozenges—are recommended across authorities for symptomatic relief though they don’t alter illness duration [2] [7] [8]. Zinc lozenges or syrup taken within 24 hours of symptom onset have some evidence of shortening colds in adults, but their effect on cough specifically is less certain and intranasal zinc carries a risk of permanent smell loss [3] [1] [4].

3. Prescription options and specialist recommendations

The pharmacologic prescription option with evidence for reducing rhinorrhea‑related cough is intranasal ipratropium bromide; guideline reviews list intranasal ipratropium as effective for nasal symptoms and cough related to secretions [3] [10]. There is no high‑quality evidence supporting corticosteroids or antibiotics for uncomplicated cold cough, and inhaled bronchodilators or NSAIDs are not routinely recommended for cough unless there is comorbid asthma or another indication [5] [9] [7].

4. Common remedies that don’t work or carry risk

Antibiotics do not treat viral colds and should not be used for routine cold‑related cough [2] [7]. Oral phenylephrine has come under regulatory scrutiny because evidence suggests the commonly recommended OTC dose is ineffective for congestion and offers no proven cough benefit [11] [5]. First‑generation antihistamines alone do not reliably relieve cough, and OTC cough‑and‑cold products are discouraged or contraindicated for young children because of safety concerns [6] [3] [8].

5. Practical, evidence‑based approach and caveats for clinicians and patients

Treat cough from a cold with supportive care first—rest, fluids, humidified air, saline—and consider honey for symptomatic relief in adults and children over 1 year; for adults, an expectorant such as guaifenesin may give small benefit and intranasal ipratropium can be prescribed when rhinorrhea drives cough, while reserving antibiotics and steroids for clear, evidence‑based indications [2] [4] [3] [8]. Clinicians and patients should note the limits of the literature—many trials are small or inconsistent—and balance modest expected benefits against risks (for example, no honey under age 1; intranasal zinc risk) and the regulatory discussions around components like phenylephrine [1] [4] [11].

Want to dive deeper?
How does intranasal ipratropium compare with placebo for cough relief in randomized trials?
What is the evidence on dextromethorphan for adult cough due to the common cold?
What are safe, evidence‑based cough treatments for children under 6 years?